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Breast cell proliferationSoy isoﬂavones (SIF) are present in the systemic circulation as conjugated forms of which the estrogenic
potency is not yet clear. The present study provides evidence that the major SIF glucuronide metabolites
in blood, genistein-7-O-glucuronide (GG) and daidzein-7-O-glucuronide (DG), only become estrogenic
after deconjugation. The estrogenic potencies of genistein (Ge), daidzein (Da), GG and DG were deter-
mined using stably transfected U2OS-ERa, U2OS-ERb reporter gene cells and proliferation was tested
in T47D-ERb cells mimicking the ERa/ERb ratio of healthy breast cells and inT47D breast cancer cells.
In all assays applied, the estrogenic potency of the aglycones was signiﬁcantly higher than that of their
corresponding glucuronides. UPLC analysis revealed that in U2OS and T47D cells, 0.2–1.6% of the
glucuronides were deconjugated to their corresponding aglycones. The resulting aglycone concentrations
can account for the estrogenicity observed upon glucuronide exposure. Interestingly, under similar
experimental conditions, rat breast tissue S9 fraction was about 30 times more potent in deconjugating
these glucuronides than human breast tissue S9 fraction. Our study conﬁrms that SIF glucuronides are not
estrogenic as such, and that the small % of deconjugation in the cell is enough to explain the slight bioac-
tivity observed for the SIF-glucuronides. Species differences in deconjugation capacity should be taken
into account when basing risk–beneﬁt assessment of these SIF for the human population on animal data.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Isoﬂavones are naturally occurring dietary compounds mostly
found in soy. Due to their structural similarity with the natural
hormone estradiol, they have weak estrogenic potencies and are
referred to as phytoestrogens (Barnes, 2010; Hwang et al., 2006;
Setchell, 1998). Many studies reported positive relationships
between soy consumption and several important health beneﬁts
like lower risks for breast cancer and heart disease, less hot ﬂushes
and nocturnal sweating, improved bone density and cognitive
health (Rong et al., 2011; Siow and Mann, 2010; Vitetta et al.,
2011). Peri- and post-menopausal women with a family history
of breast cancer are a sub-population in Western society that
increasingly is considered vulnerable for unregulated and self-
administrated consumption of dietary soy supplements (BfR,2007; Doerge et al., 2000; Maskarinec, 2013). Despite their
beneﬁcial effects for human health and large societal acceptance
by consumers, potential adverse effects as suggested in in vitro
and in vivo experiments, and in clinical trials, raise questions about
the safety of high dosages of phytoestrogens (Andres et al., 2011;
Haines et al., 2012; Rietjens et al., 2013; Steinberg et al., 2011).
However, most of the in vitro estrogenicity experiments used
biologically active aglycones, which generally make up <1–2% of
the total isoﬂavone levels present in blood (Gu et al., 2006;
Hosoda et al., 2010; Sesink et al., 2001). Glucuronides (Fig. 1) are
the predominant metabolites reported in blood plasma (around
75%, depending on the species studied), followed by sulfates
(24%) and aglycones (<1%) (Gu et al., 2006; Hosoda et al., 2010;
Sesink et al., 2001). This means that estrogen sensitive tissues will
predominantly be exposed to conjugated metabolites via the
systemic circulation.
The hydrophilic nature of these circulating glucuronide metabo-
lites probably retards their cellular uptake, unless mechanisms
exist for uptake and/or hydrolysis of these conjugates.
Furthermore, it is not clear whether these glucuronides are
biologically active or not. For example, Bolca et al. (2010) concluded
Fig. 1. Molecular structure of genistein, daidzein and their corresponding 7-O-glucuronides, the commercially available and predominant metabolites in the systemic
circulation.
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supplements rich is soy isoﬂavone (SIF), 98% of SIF reached the
breast tissue as glucuronide, whereas Yuan et al. (2012) using
different breast cancer cell lines concluded that glucuronides are
not active themselves. Some studies also suggested that these
glucuronides act as precursor of bioactive aglycones and are bioac-
tivated in the target tissues (Hosoda et al., 2010; Terao et al., 2011;
Zhang et al., 1999). In estrogen sensitive tissues, the estrogenic
responses are mediated by estrogen receptors (ERs) of which an
alpha and beta form exist. The relative occurrence of ERa and ERb
is tissue dependent, for example, ERa is predominant in the mam-
mary gland, epididymis, testis, uterus, kidney and pituitary gland
whereas more ERb than ERa is present in the prostate, bladder
and lungs (Evers et al., 2013; Kuiper et al., 1997; Pearce and
Jordan, 2004; Pfafﬂ et al., 2001). In certain types of breast cancer,
the ERa/ERb ratio is signiﬁcantly increased compared to healthy tis-
sue (Bardin et al., 2004a; Leygue et al., 1998), mainly due to a
decrease of the ERb levels (Lazennec et al., 2001; Rutherford et al.,
2000). It has been shown that ERa activation stimulates cell prolif-
eration in breast tissue, whereas ERb is involved in inhibition of
proliferation and stimulation of apoptosis (Bardin et al., 2004b;
Sotoca et al., 2008; Ström et al., 2004). Phytoestrogens such as
genistein have been shown to activate the two ERs with a greater
relative potency compared to estradiol (E2) for ERb than for ERa
(Sotoca et al., 2008; ter Veld et al., 2006). As a consequence the
potency of aglycones such as Ge or Da to suppress or induce cell
proliferation depends on the speciﬁc ratio between ERa and ERb
present in the cells studied. However, in the reported in vitro stud-
ies, no attention was paid to use ERa and ERb ratios reﬂecting the
ratios present in speciﬁc estrogen sensitive tissues. In the present
study an in vitro cell model was used where in T47D-ERb breast
cancer cells the genetically enhanced ERb levels could be
suppressed by tetracycline to achieve an ERa/ERb ratio which
according to Evers et al. (2013) is similar to that in normal human
breast tissue. This is important, given that due to differences in
ERa/ERb ratios, the effect of estrogen active compounds on inhibi-
tion or stimulation of cell proliferation can vary signiﬁcantly
between different estrogen sensitive tissues and cell models. In
addition, also the metabolic forms in which the SIF are present in
the systemic circulation and the respective tissues will determine
their ultimate biological effect. Giving the relevance of deconjuga-
tion as bioactivation step in tissues, it is important to know the
capacity for deconjugation of glucuronides by breast tissue as a tar-
get organ as well as species speciﬁc differences in deconjugationcapacity. The aim of the present study was to investigate to what
extent SIF glucuronide metabolites are estrogenic themselves or
need to be deconjugated to the corresponding biologically active
aglycones to become estrogenic, and to study to what extent
normal rat and human breast tissue is able to carry out this
deconjugation of the SIF glucuronides. To address these research
questions the U2OS-ERa and U2OS-ERb reporter gene assays, and
T47D wild type (wt) and T47D-ERb proliferation assays were used
to quantify the estrogenicity of selected SIF glucuronides and their
aglycones. Genistein-7-O-glucuronide (GG) and daidzein-7-O-
glucuronide (DG) were selected as model compounds because they
are commercially available and occur quite predominantly in the
systemic circulation (Gu et al., 2006; Hosoda et al., 2010). The
production of SIF aglycones in the cell culture experiments was
determined as well.2. Materials and methods
2.1. Chemicals
17b-estradiol (E2), genistein (Ge), daidzein (De) (with puri-
ty > 99%) were purchased from LC Laboratories (Woburn, USA).
Genistein-7-O-glucuronide (GG) and daidzein-7-O-glucuronide
(DG) were obtained from Extrasynthese (Genay Cedex, France).
Dimethyl sulfoxide (DMSO (>99%) was purchased from Acros
Organics (Geel, Belgium). Geneticin (G418) and fetal calf serum
(FCS) (Australian origin, 1099) were purchased from Invitrogen
Life Technologies (Paisley, Scotland). Dextran-charcoal-treated
FCS (DCC-FCS, SH30068.05) was obtained from Perbio Science NV
(Etten-Leur, the Netherlands). Non-essential amino acids (NEAA-
100x, 11140-035), phosphate-buffered saline (PBS) (without Ca2+
and Mg2+) and all the culture media were supplied by Gibco
(Paisley, Scotland). Trypsin 0.25 g/100 ml in PBS was obtained from
Difco (Detroit, USA). Sodium hydroxide (NaOH), ethylenedinitrote-
traacetic acid (EDTA.2H2O; Titriplex), magnesium sulphate
(MgSO47H2O), 37% HCl, and KCl were purchased from Merck
(Darmstadt, Germany). Magnesium carbonate
((MgCO3)4Mg(OH)25H2O), phenyl methyl sulfonyl ﬂuoride
(PMSF) were obtained from Aldrich (Saint Louis, MO, USA) and
dithiothreitol (DTT), Tris from Sigma (Steinheim, Germany).
Trans-1,2-diaminocyclohexane-N,N,N0,N0-tetraacetic acid monohy-
drate (CDTA) and glycerol was obtained from Fluka (Buchs,
Switzerland). Hygromycin and D-luciferin were obtained from
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was purchased from VWR International (Darmstadt, Germany)
and acetonitrile (ULC/MS) was purchased from Biosolve BV
(Valkenswaard, Netherlands). The 5-bromo-20-deoxyuridine
(BrdU) kit (colorimetric, 11647229001) was obtained from Roche
Diagnostics (Mannheim, Germany) and the Pierce BCA protein
assay kit (product number 23227) from thermo Scientiﬁc
(Rockford, IL, USA). All other cell culture reagents from Gibco
(Paisley, UK). Pooled SD male rat liver S9 was obtained from BD
Biosciences (MA, USA; batch 88875).
2.2. Cell culturing
The human osteosarcoma (U2OS) cell lines stably expressing
ERa or ERb, linked to the 3xERE-tata-luciferase gene, were provid-
ed by the Hubrecht Institute, Utrecht. They were cultured and used
as described before (ter Veld et al., 2006). Brieﬂy cells were
cultured in a 1:1 mixture of F12 and DMEM (31331-028) supple-
mented with 7.5% FCS and 0.5% NEAA. U2OS-ERa growth medium
was supplemented with selective antibiotics geneticin (200 lg/ml)
and hygromycin (50 lg/ml), while U2OS-ERb growth medium was
supplemented only with geneticin (200 lg/ml) as selection antibi-
otic. U2OS-ERa cells were used in passages 10–25 and U2OS-ERb
cells in passages 12–29 for the reporter gene assay and analysis
of metabolite formation.
T47D human breast cancer cells (T47D-wt) were purchased
from the American Type Culture Collection (Manassas, VA, USA)
and cultured in a 1:1 mixture of F12 and DMEM (31331-028) sup-
plemented with 5% FCS. T47D-wt cells were used in passages 10–
21 for the cell proliferation assay and analysis of metabolite
formation.
The T47D-ERb cell line, stably transfected to display tetracy-
cline-dependent ERb-expression was provided by Ström et al.
(2004) and used as described before (Sotoca et al., 2008). These
cells were also grown in a 1:1 mixture of F12 and DMEM
(31331-028) supplemented with 5% FCS plus 100 ng tetracycline/
ml. With this amount of tetracycline the ERa/ERb ratio becomes
comparable with that of normal human breast tissue based on
Western blot analysis carried out by Evers et al. (2013). The cells
were reselected (with 0.5 lg/ml puromycin) every 10 passages
(about 3 weeks) to prevent loss of ERb and its related expression
of enhanced green ﬂuorescent protein (EGFP) activity (Sotoca
et al., 2008). For cell proliferation experiments, cells were incubat-
ed in a 1:1 mixture of DMEM and F12 without phenol red,
supplemented with 5% DCC-FCS, 0.5% NEAA and the amount
of tetracycline needed to obtain the desired ERa/ERb ratio
(100 ng/ml to mimic normal human breast cells). T47D-ERbcells
were used in passages 33–49 for the cell proliferation assays.
2.3. Reporter gene assays
Reporter gene assays were performed using human osteosarco-
ma cells (i.e. U2OS-ERa and U2OS-ERb). These cells are devoid of
endogenous ERs but have been transfected with either any of the
ER and stably express 3xERE-tata-Luc (Quaedackers et al., 2001).
As a result, the amount of luciferase produced is a direct indication
of the amount of estrogen-mediated gene expression via ERs (ter
Veld et al., 2006; van der Woude et al., 2005). These two cell lines
are ideal models for measuring ER-isotype speciﬁc transcriptional
activity. Reporter gene assays were performed using the method
described before (Sotoca et al., 2008; ter Veld et al., 2006). In brief,
80–90% conﬂuent ERa/b-U2OS-Luc cells were washed with PBS,
trypsinized and transferred to phenol-red free assay medium,
and seeded in the inner 60 wells of a 96-well plate at 100 ll/well
at a density of 105 cells/ml (ERa-U2OS-Luc) or 7.5  104 cells/ml
(ERb-U2OS-Luc). Plates were incubated at 37 C and 5% CO2. Theassay medium was renewed after 24 h of incubation. At 48 h,
100 ll of assay medium containing the test compounds (E2, Ge,
Da, GG or DG at indicated concentrations) were added. All test
compounds were dissolved in DMSO and the ﬁnal concentration
of DMSO was 0.4% in each well. Compounds were tested in tripli-
cate; outer rows of the 96-well plate were ﬁlled with 200 ll of
sterile PBS to prevent evaporation from the inner 60-wells of the
plate. The exposure concentrations were 0.03–400 lM for both
U2OS-ERa and U2OS-ERb cells. After 24 h exposure, cells were
washed with 100 ll diluted PBS (1/2  PBS in demineralised
water) which was subsequently replaced by 30 ll of a hypotonic
low-salt buffer (10 mM Tris–HCl pH 7.8 containing 2 mM DTT
and 2 mM CDTA). To lyse the cells the plate was then placed on
ice for 10 min to allow swelling and subsequently frozen at
80 C for at least 30 min. Before measuring, the plates were
thawed and brieﬂy shaken until reaching room temperature.
Using a luminometer (Thermo LabSystems Luminoskan Ascent)
estrogen-mediated luciferase production in the ERa-U2OS-Luc
and ERb-U2OS-Luc cells was measured at room temperature as
described before (ter Veld et al., 2006).
2.4. Cell proliferation assays
As functional measure of estrogenicity, the estrogen-dependent
cell proliferation of T47D-wt breast cancer cells and T47D-ERb cells
was used. The T47D-ERb cells with tetracycline dependent inhibi-
tion of expression of ERb allowed mimicking the ERa/ERb ratio of
normal rat and human breast tissue (Evers et al., 2013). The cell
proliferation assay was performed using the method described by
Sotoca et al. (2010). In brief, 80–90% conﬂuent T47D cells were
washed with PBS, trypsinized and transferred to phenol-red
free assay medium supplemented with 5% DCC-FCS. Cells
(1.8  105 cells/ml) were seeded in the inner 60 wells of a 96-well
plate at 100 ll/well and incubated overnight at 37 C plus 5% CO2.
The assay medium was renewed after 24 h of incubation. At 48 h,
100 ll of assay medium containing the test compounds in DMSO
(ﬁnal conc. 0.4%) was added. Compounds were tested in triplicate
and outer rows of the 96-well plate were ﬁlled with 200 ll of ster-
ile PBS. After 48 h of exposure of cells with different concentrations
of SIF, cell proliferation was determined following the BrdU
Roche’s colorimetric protocol using a multi-mode microplate read-
er (SpectraMax

M2). Based on the DNA synthesis, the BrdU
method provides an indirect and precise indication of cell
proliferation.
2.5. Measuring deconjugation of glucuronides in cell models
Exposure of the cells in phenol red-free assay medium was per-
formed according to exposure protocols mentioned earlier in the
cell proliferation assay section, with the exception that 24 well
plates were used, and that exposure was limited to 20 lM and
400 lM GG or DG for 24 h. After the exposure, the medium was
collected and cells were washed with PBS. Then cells were harvest-
ed and lysed in cold 65% aqueous methanol (St Gelais et al., 2012).
All samples were stored at 20 C until analysis.
2.6. Preparation of rat and human breast tissue S9 fractions
As breast tissue S9 fractions of rat or human are not commercial-
ly available, these S9 fractions were prepared from available tissue
samples. Four samples of anonymous human breast tissuemedical-
ly judged to be normal were kindly provided by the Maastricht
UniversityMedical Center under ethical approval. Rat breast tissues
were pooled from 5 control female F344 rats in a study approved by
the Animal Welfare Committee of Wageningen University
(Wageningen, The Netherlands). Frozen breast tissue samples
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were thawed in a Petri dish on ice and cut into small pieces. The tis-
sues were placed in a 12 ml Greiner tube and immersed with three
times the tissue volume of ice-cold 100 mM Tris–HCl (pH 7.4) con-
taining 20% glycerol, 150 mM KCl, 1 mM EDTA, 0.2 lM DTT and
0.2 mM PMSF. The buffer was stored at 20 C because of the lim-
ited stability of DTT and PMSF. Homogenization was done with an
Ultra-Turrax T25 homogenizer (Janke & Kunkel IKA

Labortechnik,
Germany) followed by centrifugation (Sigma 4K10, Osterode,
Germany) at 9000g for 15 min at 4 C. After removing the fat layer
from the top, the supernatant was collected as subcellular S9 frac-
tions and stored at80 C in small aliquots until use. Taking one ali-
quot of each S9 sample, the protein concentration was determined
with a Pierce BSA protein assay kit (Thermo Scientiﬁc, Rockford,
USA). As commercial human or rat breast tissue S9 is not available,
we validated our S9 preparation procedure by comparing the
deconjugation activity of the S9 fraction we prepared from F344
ovariectomized rat liver with that of commercially available SD
male rat liver S9 (Supplementary document 1).
2.7. Glucuronide deconjugation by breast tissue S9 fractions
Rat and human breast tissue S9 fractions were incubated with
GG and DG to study their deconjugation potency. To this end
40 lM of each glucuronide was incubated for 24 h at 37 C with
0.1 mg/ml S9 protein. The reaction was started by adding 0.4 ll
of GG or DG from a 200 times concentrated stock solution (pre-
pared in DMSO) in 99.6 ll of 100 mM Tris–HCl (pH 7.4) buffer (to-
tal volume 100 ll), and terminated by adding 25 ll ice-cold
acetonitrile. Samples were analyzed immediately.
2.8. UPLC analysis of SIF glucuronides and aglycones
All samples of the deconjugation experiments were analysed
using a Waters Acquity™ UPLC (Ultra Performance Liquid
Chromatography system; Milford, MA, USA) which consists of a
binary solvent manager, sample manager and photodiode array
(PDA) detector, equipped with a Water Ethylene Bridged Hybrid
(BEH) C18 1.7 lm 2.1  50 mm column (Water, Ireland).
Nanopure water with 0.1% TFA and 100% acetonitrile were used
as solvent A and B, respectively. After thawing and centrifugation
at 13,000g for 5 min at 4 C, samples were pipetted (70–80 ll) in
special UPLC vials and placed in a plate sampler. The injection vol-
ume for UPLC analysis was 3.5 ll and the ﬂow rate was 0.6 ml/min.
Elution was started with 0% solvent B followed by an increase of
solvent B from 0 to 10%, 15%, 50% and 80% at 0.58, 2.85, 4.28 and
4.40 min, respectively. The 80% solvent B condition was kept until
4.52 min, thereafter the % of solvent B was reduced to 0% at
4.63 min and maintained at that percentage until 5.80 min. PDA
spectra were analysed between 200–360 nm and the chro-
matograms acquired at 260 nm were used for quantiﬁcation of
the amount of isoﬂavone aglycones and glucuronides using calibra-
tion curves of commercially available reference compounds. Using
the above mentioned UPLC conditions the retention times of differ-
ent test compounds were as follows: genistein 3.78 min (UVmax
260 nm); daidzein 3.41 min (UVmax 249 nm); GG 2.81 min (UVmax
259.4 nm) and DG 1.96 min (UVmax 249 nm).
2.9. Data analysis
The plate to plate variation in the E2-control responses within
and between experiments (<1.4 fold difference) was corrected
based on the response of 10 pM E2 for U2OS-ERa and 200 pM E2
for U2OS-ERb cells. Plate to plate variation for the proliferation
assays with T47D-wt and T47D-ERb cells was corrected based on
the response induced by the vehicle control (0.4% DMSO) whichwas set at 100% proliferation. Dose–response curves were ﬁtted
using Graphpad Prism version 5.02, Graphpad Software (San
Diego, CA). The relative light units (RLUs) in every well of the
U2OS-Luc reporter gene assays were standardised by setting the
response of the vehicle control (DMSO 0.4%) at 0% induction and
the maximum luciferase induction obtained by E2at 100%. The
concentration of the test chemical eliciting transcriptional activity
equivalent to 10% of the positive control value, was deﬁned as PC10
and that equivalent to 50% as PC50 (EPA, 2011). For the more
potent compounds like Ge and Da, also the PC50 values were deter-
mined. Estradiol equivalency factors (EEF) were calculated based
on the PC10 or PC50 values as EEF(PC10) = PC10(E2)/PC10 (com-
pound) and EEF(PC50) = PC50(E2)/PC50 (compound). Unless stated
otherwise, the effect concentrations were calculated from three
independent experiments in triplicate.3. Results
3.1. Estrogenic potency of aglycones and glucuronides
Fig. 2 shows the dose response curves for the estrogenic activity
of genistein (Ge), daidzein (Da) and their corresponding 7-O-glu-
curonides (GG and DG) in the U2OS-ERa and U2OS-ERb reporter
cell lines together with E2. The potency order was the same in both
the U2OS-ERa and U2OS-ERb cell line, namely E2 > Ge >
Da > GG > DG (Table 1). The effective concentration of E2 was low-
er in the U2OS-ERa than in theU2OS-ERb, whereas for the SIF this
was the opposite. This result is in line with other reports (Kwack
et al., 2009; Sotoca et al., 2008; ter Veld et al., 2006). The estradiol
equivalency factor (EEF) values for PC10 and PC50 obtained with
both cell lines (Table 1) show that Ge was 5–9 fold more potent
than Da, and GG was 10–18 fold more potent compared to
DG. The SIF and their corresponding glucuronides yield a higher
maximum activity than E2 (Table 1), which in both ER-transfected
cells was up to >200% of the maximum induction by E2.3.2. Proliferation effects of soy isoﬂavones (aglycones and
glucuronides)
Fig. 3 presents the dose-dependent induction of cell
proliferation in the T47D-wt human breast cancer cell line, by
the glucuronides and their corresponding aglycones, compared to
estradiol (E2). Interestingly, low concentrations of compounds con-
sequently reduced the proliferation compared to that of the DMSO
control, and at higher exposure concentrations the proliferation
increases in a dose-related manner. Low concentrations of the SIF
reduce the proliferation more than E2, and at high concentrations
the maximum proliferation induced by the aglycones is higher
than that of E2 (Table 2).
The proliferation potencies, expressed as estradiol equivalency
factors (EEF), of Da and Ge in the T47D-wt cells, were similar,
but the potency of GG was about a factor of 5 higher than that of
DG.
Fig. 4 presents the dose-dependent increase in proliferation of
T47D-ERb cells with an ERa/ERb ratio mimicking the ERa/ERb ratio
in normal rat and human breast tissue by addition of 100 nM tetra-
cycline (Evers et al., 2013). Again, low concentrations of the SIF
reduced the proliferation as compared to E2, and at high concen-
trations the maximum proliferation induced by the aglycones is
higher than that of E2 (Fig. 4 and Table 3), although the differences
were less obvious than with the T47D-wt cells. All the aglycones
and their glucuronides show lower proliferation potency (higher
PC10 values) compared to E2. The proliferation potency of Da
expressed as EEF, was 6–29 fold higher than that of Ge. This differ-
ence was not observed in T47D-wt cells and in the reporter gene
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Fig. 2. Induction of ERE-mediated Luc activity in the U2OS-ERa (A and C) and U2OS-ERb (B and D) cells upon exposure to increasing concentrations of E2 (d), Ge (j) and GG
(}) (A and B) and of E2 (d), Da (j) and DG (}) (C and D). Induction was expressed relative to the maximum E2 response set at 100%. Data points represent the mean of
triplicate determinations ± standard deviation.
Table 1
The estrogenic potency of SIF expressed as potency concentrations (PC10 and PC50) of genistein (Ge), genistein-7-O-glucuronide (GG), daidzein (Da) and daidzein-7-O-
glucuronide (DG) compared to E2 in the U2OS-ERa and U2OS-ERb cells. Also estradiol equivalency factor (EEF) at PC10 and PC50, the concentrations for maximum estrogenic
effect and the maximum induction relative to E2 (max set at 100%) are presented.
Compound PC10 EEF at PC10 PC50 EEF at PC50 Conc. giving maximum
level of induction (lM)
Maximum induction
relative to E2 (%)
U2OS ERa E2 0.4 pM 1 2.6 pM 1 1 ⁄ 105 100
Ge 2.9 nM 1.4E04 16.2 nM 1.6E04 6.3 172
GG 1.3 lM 3.1E07 3.9 lM 6.7E07 400 206
Da 25.7 nM 1.6E05 75.9 nM 3.4E05 73 224
DG 12.6 lM 3.2E08 38.9 lM 6.7E08 400 219
U2OS ERb E2 7.6 pM 1 40.7 pM 1 2 ⁄ 104 100
Ge 0.4 nM 1.9E02 1.9 nM 2.1E02 6.0 182
GG 0.3 lM 2.5E05 1.3 lM 3.1E05 400 191
Da 3.2 nM 2.4E03 13.8 nM 3.0E03 6.0 203
DG 5.5 lM 1.4E06 22.9 lM 1.4E06 400 157
Fig. 3. Proliferation effect of E2 (d), Ge (j) and GG (}) (A) and E2 (d), Da (.) and DG (}) (B) in T47D-wt type cells. Data are presented after normalized with respect to the
proliferation of control cells set at 100%. Data points represent the mean of triplicate determinations ± standard deviation.
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Table 2
Cell proliferation induced by SIF expressed as proliferation potency concentrations (PC10 and PC50) of genistein (Ge), genistein-7-O-glucuronide (GG), daidzein (Da) and
daidzein-7-O-glucuronide (DG) compared to E2 in T47D-wt cells. Also estradiol equivalency factor (EEF) at PC10 and PC50, the concentrations inducing maximum proliferation
and the maximum proliferation to the vehicle control (DMSO 0.4%) set at 100% are presented.
Compound PC10 EEF at PC10 PC50 EEF at PC50 Conc. of maximum
proliferation (lM)
Maximum proliferation relative
to vehicle control (%)
T47D-wt E2 0.8 pM 1 4.2 pM 1 2 ⁄ 105 163
Ge 60.3 nM 1.3E05 191 nM 2.2E05 2 185
GG 7.4 lM 1.1E07 21.4 lM 2.0E07 400 162
Da 61.7 nM 1.3E05 186 nM 2.3E05 6 227
DG 32.4 lM 2.5E08 107 lM 3.9E08 400 174
Fig. 4. Proliferation effect of E2 (d), Ge (j) and GG (}) (A) and E2 (d), Da (.) and DG (}) (B), in T47D-ERb cells when exposure medium contains 100 ng/ml tetracycline to
mimic the ERa/ERb ratio in normal breast tissue. Data are presented after normalized with respect to the proliferation of control cells set at 100%. Data points represent the
mean of triplicate determinations ± standard deviation.
Table 3
Cell proliferation induced by SIF expressed as proliferation potency concentrations (PC10 and PC50) of genistein (Ge), genistein-7-O-glucuronide (GG), daidzein (Da) and
daidzein-7-O-glucuronide (DG) compared to E2 in T47D ERb cells. Also the estradiol equivalency factor (EEF) at PC10 and PC50, the concentrations inducing maximum
proliferation and the maximum proliferation to the vehicle control (DMSO 0.4%) set at 100% are presented.
Compound PC10 EEF at PC10 PC50 EEF at PC50 Conc. giving maximum level
of proliferation (lM)
Maximum proliferation relative
to vehicle control (%)
T47D-ERb E2 1.6 pM 1 24.5 pM 1 6 ⁄ 105 120
Ge 81.3 nM 2.0E05 200 nM 1.2E04 0.6 131
GG 3.0 lM 5.3E07 7.8 lM 3.1E06 40 122
Da 2.8 nM 5.7E04 35.5 nM 6.9E04 6 141
DG 126 lM 1.3E08 >400 lM >4.0E09 400 105
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were about 100-fold less potent than their respective aglycones
(Tables 2 and 3).
3.3. In vitro deconjugation study
3.3.1. Cell lines
The UPLC chromatograms (Fig. 5a–c) show the deconjugation of
GG to Ge as detected by analysis of the cell culture medium and the
intracellular content after incubation for 24 h with U2OS (ERa or
ERb) and T47D-wt cells. Incubation of 400 lM GG results in the
formation of 2.4–6 lM of Ge (0.6–1.5%). A similar deconjugation
pattern was found when incubated with DG (data not shown).
T47D-wt cells were 1–3 fold less efﬁcient in deconjugation of
glucuronide metabolites than U2OS (ERa or ERb) cells. The chro-
matograms reveal that glucuronide metabolites remain the pre-
dominant compounds (i.e. P99%) and upon incubation with the
cells only a small portion (maximum about 1.6%) of the SIF glu-
curonides were converted to the corresponding aglycones
(Table 4). At similar incubation conditions the concentration ofgenistein produced was 4–7 fold higher compared to that of
daidzein. A small portion (0.1–0.2% i.e. 0.1–0.7 lM) of glucuronide
conjugates was detected in the intracellular extract, where no agly-
cones were detected (Fig. 5 and Table 4).
Incubation of 20 lM of GG or DG SIF with the same cell lines
yielded comparable results, where the glucuronide conjugates
were the predominant compounds (98%) and the deconjugated
aglycones were hardly detectable (<2%), close to the limit of
detection (0.1 lM) (data not shown).
3.3.2. Tissue S9 model
Fig. 6 shows the fate of GG and DG when incubated for 24 h
with S9 fractions prepared from normal human or rat breast
tissues. Results obtained under similar incubation conditions
reveal a large inter-species difference with a 24–32 fold larger
deconjugation into bioactive aglycones by rat than human
breast tissue S9. Under the conditions applied, the average total
deconjugation after 24 h by human breast tissue S9 was 2.4%
and 2.0% or 0.007 and 0.005 nmol/min/mg S9 protein or
0.0044 and 0.0035 nmol/min/g breast tissue for GG and DG,
Fig. 5. UPLC chromatograms of culture medium and intracellular content after
incubations of GG with (A) U2OS-ERa, (B) U2OS-ERb and (C) T47D-wt cells.
Chromatogram sequences (front to back) are – GG at T0; GG and Ge at T24 h; and
intracellular GG at T24 h.
Table 4
Deconjugation of 400 lM genistein-7-O-glucuronide (GG) into genistein (Ge) and
daidzein-7-O-glucuronide (DG) into daidzein (Da) after 24 h incubation with U2OS-
ERa, U2OS-ERb and T47D wild type cells (concentration and % of the total amount of
compound). Also the intracellular concentration of the glucuronides were
determined.
Cell line Compound Concentration (lM) % of total
U2OS-ERa GG 393.50 98.2
Ge 6.50 1.6
Intercellular GG 0.68 0.2
DG 399.11 99.6
Da 0.89 0.2
Intercellular DG 0.54 0.1
U2OS-ERb GG 394.70 98.6
Ge 5.30 1.3
Intercellular GG 0.29 0.1
DG 398.93 99.5
Da 1.07 0.3
Intercellular DG 0.61 0.2
T47D wt GG 397.56 99.2
Ge 2.44 0.6
Intercellular GG 0.77 0.2
DG 399.35 99.6
Da 0.65 0.2
Intercellular DG 0.62 0.2
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0.19 and 0.16 nmol/min/mg S9 protein or 0.013 and
0.011 nmol/min/g breast tissue for GG and DG, respectively
(Table 5).4. Discussion
Supplements containing SIF are frequently used by peri- and
post-menopausal women for their putative beneﬁcial health
effects. As a result levels of isoﬂavone metabolites in the blood of
these women can reach up to 2 lM, especially in the form of
glucuronide conjugates (Gu et al., 2006; Yuan et al., 2012; van der
Velpen et al., 2013). However, the estrogenicity of these circulating
glucuronidemetabolites is not clear. In the present study the intrin-
sic estrogenicity and effects on breast cancer cell proliferation of SIFglucuronides and aglycones were measured in cellular models,
including the T47D-wt cells inwhich the expression of ERb is hardly
present, and the T47D-ERb cell model in which the cellular ERa/ERb
ratio can be modulated to reﬂect the level in normal human breast
tissue (Evers et al., 2013). To the best of our knowledge this is the
ﬁrst in vitro study quantifying the proliferative effect of SIF glu-
curonide metabolites and aglycones on T47D-wt and T47D-ERb
cells that mimic in their ERa/ERb ratio in cancer and normal human
breast tissue, respectively. In addition, the species dependent
deconjugation potency of glucuronide metabolites was compared
using S9 fractions, prepared from normal rat and human breast
tissue.
The intrinsic estrogenic potency of Ge, Da and their correspond-
ing 7-O-glucuronide metabolites was quantiﬁed in reporter gene
assays using ERa or ERb speciﬁc human osteoblast (U2OS) cell
models. The intrinsic estrogenic potency of the glucuronide
metabolites was 450–1730 fold lower than that of the correspond-
ing aglycones (Table 1). In the proliferation assay with T47D-wt
cells the proliferative potency of the glucuronides was also 123–
525 fold lower than that of the corresponding aglycones
(Table 2). This result is in line with the considerably lower relative
binding afﬁnity to ERs for Ge and Da glucuronides as reported by
Zhang et al. (1999), and is also expected because in many cases
conjugation (i.e. glucuronidation) acts as a detoxiﬁcation reaction.
The PC10 and PC50 concentrations for both aglycones and glu-
curonides were 5–8 and 2–4 fold lower in the U2OS-ERb compared
to U2OS-ERa reporter gene assay, respectively, conﬁrming their
ERb selectively in contrast to the ERa selectivity of E2. The dose
response curve of Ge and Da were biphasic and the second part
of the curve reaches a higher maximum than the E2-curve. This
phenomenon was previously suggested to be related to multiple
ERE’s in the reporter construct or to stabilization of luciferase at
higher concentrations of Ge (Montano et al., 2010; Sotoca et al.,
2010).
The cell proliferation induced by SIF was tested in T47D-ERb
cells and T47D-wt cells. The ERa/ERb ratio of the T47D-ERb cells
has been made comparable with normal breast tissue by incubat-
ing them with the proper amount of tetracycline (Evers et al.,
2013). In T47D-wt cells, on the other hand, the ERb expression is
negligible resulting in a much higher ERa/ERb ratio. In both cell
lines the order of estrogenicity was the same (Tables 2 and 3) as
in the reporter gene assays (i.e. E2 > Ge > Da > GG > DG) (Table 1).
Again, the aglycones showed much higher (36–>4500 fold) poten-
cies than their corresponding glucuronides (Table 3). Interestingly,
the maximum proliferation relative to control was 50% less in the
T47D-ERb cells with the ERa/ERb ratio resembling normal breast
tissue than in the T47D-wt cells with insigniﬁcant amounts of
ERb (Tables 2 and 3 and Figs. 3 and 4). This result is in accordance
with the earlier reported decrease in proliferation with increasing
ERb levels (Sotoca et al., 2008). It is an important ﬁnding that
breast cell proliferation induced by SIF is much (50%) less in cells
that mimic the ERa/ERb ratio of normal breast tissue.
Interestingly, lower concentrations of SIF reduced the cell pro-
liferation up to 35% below those of the solvent control (Table 6).
Depending on the nature of the soy supplement used (e.g. ferment-
ed products provide higher plasma concentration), plasma concen-
trations of SIF in women taking these supplements can raise up to
2 lM (Gu et al., 2006; Yuan et al., 2012; van der Velpen et al.,
2013). In this concentration the percentage of aglycones could be
1–4%, which corresponds to 20–80 nM. Our results (Figs. 3 and 4
and Table 6) indicate that if this concentration of 20–80 nM is in
the form of genistein, which is the most active isoﬂavone reported
so far, this would lead to an inhibition or no proliferation of breast
cancer cells rather than to a stimulating effect. As can be seen in
Table 6, also the glucuronide concentrations found in blood inhib-
ited cell proliferation in our in vitro experiments. Thus based on
Fig. 6. UPLC chromatograms showing deconjugation of SIF glucuronides (i.e. formation of aglycones) by S9 fractions prepared from four normal human breast tissue samples
and 1 pooled rat sample (indicated with R) after 24 h incubation with glucuronide GG (A) and DG (B). In all the incubation, protein concentration in the S9 fractions were
0.1 mg/ml. The chromatograms were extracted at 260 nm wavelength and presented front to back in the following order: nanopure water, blank incubation (i.e. only
substrate without S9 protein), incubations with four human samples and one rat sample (R), for both GG (A) and DG (B).
Table 5
Deconjugation of genistein-7-O-glucuronide (GG) into genistein (Ge) and daidzein-7-
O-glucuronide (DG) into daidzein (Da) upon incubation with normal human (1–4)
and rat (5) breast tissue S9 fractions. Incubations were performed with 0.1 mg/ml S9
protein for 24 h using a substrate concentration of 40 lM, and analysed with UPLC.
Substrate Breast tissue
S9 sample
% Deconjugation
after 24 h
Deconjugation rate
(nmol/min/mg
S9 protein)
(nmol/min/g
breast tissue)
GG 1 2.1 0.0058 0.0030
2 2.4 0.0067 0.0026
3 2.4 0.0067 0.0051
4 2.9 0.0081 0.0068
5 (rat) 69.3 0.1925 0.0132
DG 1 1.8 0.0050 0.0026
2 1.9 0.0053 0.0020
3 2.0 0.0056 0.0042
4 2.2 0.0061 0.0051
5 (rat) 58.3 0.1619 0.01109
Table 6
Concentrations of SIF genistein (Ge), genistein-7-O-glucuronide (GG), daidzein (Da)
and daidzein-7-O-glucuronide (DG) in which inhibition of proliferation observed by
human breast cancer cell lines.
Cell lines Compound Concentration
inhibiting
proliferation
(nM)
Concentration
giving highest
inhibition
(nM)
Maximum
inhibition to
vehicle
control (%)
T47D wt Ge 0–30 9 32
GG 0–2000 200 35
Da 0–60 30 20
DG 0–20,000 6000 24
T47D-ERb Ge 0–9 1 10
GG 0–2000 60 16
Da ND ND 0
DG 0–40,000 200 6
ND = not detected.
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proliferative effects of SIF are to be expected at physiologically
relevant concentrations, concentrations that could occur in women
taking soy supplementation. Surprisingly, even T47D wt cells with
a higher than normal ERa/ERb ratio did not show proliferation
when exposed to physiologically relevant SIF concentrations. This
ﬁnding, together with the other positive health effects of SIF such
as reducing the blood lipid levels (Bairey Merz et al., 2006;Legette et al., 2011; Novotny et al., 1975), might contribute to
the beneﬁcial instead of adverse effects of soy supplementation
observed in epidemiological and clinical trials.
To detect the fate of the genistein or daidzein 7-O-glucuronides
in the in vitro cell models, U2OS-ERa, U2OS-ERb and T47D-wt cells
were exposed to 20 and 400 lMof each glucuronide for 24 h. These
concentrations were chosen as 20 lM is the average PC50 concen-
tration and the highest stimulation of cell proliferation was found
at 400 lM of the glucuronides (Tables 1–3). The results indicate
that upon exposure of the cells to 400 lM glucuronides only 0.2–
1.6% of these conjugates is converted to the corresponding
aglycones resulting in a ﬁnal aglycone concentration of about
0.7–6.5 lM (Table 4). These aglycone concentrations are higher
than their PC50 values observed in the reporter gene assay
(Table 1) and high enough to induce maximum cell proliferation
(Table 2). As the absence of traces of aglycone impurities in the glu-
curonide stocks has been conﬁrmed in advance (see Supplementary
document 2 & 3), it is concluded that in cellular reporter gene
assays or in proliferation assays with the SIF glucuronides, the
low percentage of the glucuronides converted into the correspond-
ing aglycones can account for the effects observed. This ﬁnding is
important and according to our knowledge this has not been report-
ed so far. This is also in line with the results of Yuan et al. (2012)
who exposed MCF-7 and T47D cells to genistein-7-O-glucuronide
and found that the proliferative effects correlated with the degree
of deconjugation of genistein-7-O-glucuronide.
Deconjugation canbe an important factor in bio-activation of cir-
culating SIF glucuronides in target tissues. In a previous study we
demonstrated natural deconjugation and conjugation of major SIF
by intestinal and liver S9 fractions of rat and human (Islam et al.,
2014). In this study, we focus on the deconjugation of SIF glu-
curonides by rat and human normal breast tissue S9. Although not
enough rat breast tissue was available to allow for detailed kinetic
studies as done before for deconjugation of the isoﬂavone glu-
curonides by rat and human intestinal and liver S9 fractions
(Islam et al., 2014), the HPLC chromatograms of the resulting incu-
bations (Fig. 6) revealed that limitation of the substrate concentra-
tion under the experimental condition applied was not the cause of
themarked difference in overall deconjugation between human and
rat tissue. Under the experimental conditions applied rat breast S9
appeared to be highly capable to deconjugate about 60–70% of GG
and DG within 24 h. In contrast to this, under the same incubation
conditions human breast S9 deconjugated only 2–3% of the SIF
glucuronide. For both GG and DG the deconjugation capacity of
rat breast tissue S9 appeared to be about 30 fold higher than that
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where higher levels of genistein (around 10% of the level of the glu-
curonide)were observed in rat plasma (Singh et al., 2010) compared
to human (about 1–2%) (Gu et al., 2006; Hosoda et al., 2010). Only
one publication (Setchell et al. (2011)) reports that the circulating
concentrations of IF aglycones in rats were markedly higher than
those in human volunteers. However, the rats and humans in this
study were dosed with IF aglycones from different sources, follow-
ing different administration schedules and the animalswere treated
with a 4–30 fold higher dose level than the human volunteers.
Therefore, the higher IF-aglycone concentrations in the plasma of
rats than of humans may be due to the higher dose levels used in
the rat studies, and from these data no conclusion can be drawn
about the relative presence of the glucuronide vs the aglycone in
blood under comparable dosing conditions. Thus species differences
in the deconjugation activity should be taken into accountwhen risk
and/or beneﬁt assessment of these SIF for the human population is
based on animal data. In this respect it can be suggested that if the
deconjugation reaction in the enzymatic micro-environment is not
active enough, potential health effects of SIF may not take place. It
was reported by Bartholome et al. (2010) and Shimoi (2004) that
the production of b-glucuronidase, which is involved in deconjuga-
tion, is higher in inﬂammatory sites than in normal tissue. The
results of the present study suggest that normal healthy breast tis-
sue may be relatively insensitive to the estrogenic effects of SIF
because deconjugation by b-glucuronidase is relatively low com-
pared to inﬂammatory tissues and the level of ERb is relatively high
as compared to cells from tumour tissues. Although the breast
tissues used in this study were judged to be normal by the
Maastricht University Medical Center, we did not quantify the
relative and absolute speciﬁc ER levels. It is therefore important to
further study the ERa/ERb ratio as well as the absolute ER-levels
in a more elaborate series of breast tissue samples from women
with a variety of breast health conditions and to optimize the kinetic
parameters.
In conclusion, our results show that SIF glucuronides are not
estrogenic as such, but have to be deconjugated to become bioac-
tive. Under the experimental condition applied we also show that
species differences may play an important role in deconjugation of
SIF glucuronides. These ﬁndings should be taken into account dur-
ing risk–beneﬁt assessment of these SIF together with the other
bioactive metabolites such as equol produced by some speciﬁc
gut microbes and by equol producing (post)menopausal women.
Of course the exposure to SIF in the present in vitro studies are
relatively short compared to the long term human exposure to
the same SIF supplement, and the ultimate internal exposure con-
centration and resulting health effect may be inﬂuenced by for
example accumulation of the SIFs in fatty tissue. Nevertheless,
our in vitro results suggest that soy supplement intake by post-
menopausal women will not induce proliferation of normal breast
tissue and may even inhibit proliferation. Of course further in vivo
research is needed to conﬁrm this hypothesis.Funding
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